aTYR PHARMA INC — Director's Dealing 2024

Jan 9, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2024-01-05

Reporting Person: Broadfoot Jill Marie (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-01-05	Employee Stock Option (right to buy)	$1.50	A	150000	Acquired	2034-01-05	Common Stock (150000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	18661	Direct

Footnotes

F1: Includes 1,025 shares acquired on May 15, 2023 and 2,176 shares acquired on November 15, 2023 under the Company's 2015 Employee Purchase Plan.

F2: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning February 5, 2024, such that this option will be fully exercisable on January 5, 2028. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer.